30 June 2022 - - UK-based artificial intelligence -enabled drug discovery company MultiOmic Health and digital health startup Mesh Bio have formed partnership to conduct an observational clinical study on patients with chronic metabolic disease and increased risk of complications such as chronic kidney disease, the companies said.

The partnership will provide access to data from patient populations in Asia that have historically been underrepresented in chronic metabolic disease studies.

Mesh will collaborate with its network of healthcare provider customers to recruit patients for the study.

MultiOmic will generate genomic, proteomic, metabolomic and potentially other omics data from anonymized body fluid samples.

These will be combined with anonymized data from clinical and diagnostic tests for both companies to build a rich multi-omics dataset and derive AI-based computational biology models.

The study will enable MultiOmic and Mesh to progress their respective R and D programs to develop precision therapeutic and diagnostic products that will transform the lives of patients with metabolic syndrome-related conditions.

They will also jointly conduct collaborative projects to enhance patient stratification for other biopharma and medtech companies' clinical-stage R and D programs.

Metabolic syndrome-related conditions such as type 2 diabetes mellitus, chronic kidney disease, atherosclerotic cardiovascular disease (ASCVD), non-alcoholic fatty liver disease (NAFLD) and polycystic ovary syndrome arise from a common set of risk factors present in half the world's adult population.

These age-related conditions can lead to serious consequences, including heart attack, stroke, blindness, nerve damage, foot amputation, kidney dialysis and liver failure.

Prior to the COVID-19 pandemic, they accounted for half the world's deaths and nearly USD 2tn in global healthcare spending.

This burden will be further exacerbated by the pandemic.

A significant proportion of COVID-related hospitalizations and fatalities arose in patients with metabolic syndrome conditions and recent studies have indicated that COVID survivors have an increased risk of being diagnosed with T2D3 and CKD4.

Mesh Bio is a digital health startup focused on addressing the growing global clinical burden of metabolic diseases driven by an aging population, and challenges in care delivery.

Mesh Bio develops clinical decision support analytics and automation solutions for management of chronic disease, such as cardiovascular disease and type 2 diabetes.

These solutions enable data driven care delivery, improving patient engagement, and health outcomes. Mesh Bio's DARA is a Health Intelligence Platform that empowers precision clinical intervention at scale.

Predictive analytics on multidimensional health data streams and clinical workflow automation enables health care providers to enhance operational efficiency, personalize care delivery and increase patient engagement.

MultiOmic Health is an AI-enabled drug discovery company dedicated to chronic multi-factorial diseases, with an initial focus on the metabolic syndrome-related conditions.